Monoclonal antibody anti-PBP2a protects mice against MRSA (methicillin-resistant Staphylococcus aureus) infections.

摘要: Methicillin-resistant Staphylococcus aureus (MRSA) is a multidrug-resistant bacterium responsible for serious nosocomial and community-acquired infections worldwide. Since few antibiotics are effective treating MRSA infections, the development of new therapies great importance. Previous studies demonstrated that PBP2a target generates protective antibodies against MRSA. A murine monoclonal antibody (MAb) recognizes from strains was previously isolated characterized. In this report, we evaluated biodistribution MAb in blood tissues, as well extent protection conferred using prophylactic therapeutic assays compared to vancomycin treatment. Biodistribution 12-96 h after administration. It predominantly remained serum, but it also detectable kidneys, lungs, spleen at low concentrations (about 4.5% 1.9% 0.7% spleen) all observed timepoints. Prophylactic model significant bacterial load reduction kidneys groups treated with either IgG (greater than 3 logs) or F(ab')2 (98%) when control (untreated). Mice were challenged lethal dose, survival rate higher mice. Treatment resulted similar mice vancomycin, MAb/vancomycin combination therapy effective. These results demonstrate an anti-PBP2a may be promising infections.